Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Open Orphan pharma spin-out Poolbeg Pharma present at London South East's October live event


We were delighted to welcome Jeremy Skillington and Cathal Friel, CEO and Chairman at Open-Orphan (ORPH) spin-out Poolbeg Pharma (POLB), an infectious diseases specialist.

In July Poolbeg Pharma IPO'd on AIM, raising £25M, a pot of money which the team intend to use to develop 5 or 6 core assets which can then be sold on to Big Pharma companies.

The company has already inherited a Phase II ready influenza immune-modulater, and says it hopes to acquire new assets and licences.

Watch out for acquisition announcements in the weeks and months ahead say the company.

Poolbeg is targeting the infectious diseases market, which is expected to exceed $250 bn dollars by 2025. POLB’s initial assets come from Open Orphan, the infectious disease and human challenge trials business, which means Poolbeg has access to knowledge, experience and clinical data from 20 years of clinical challenge trials.

This webinar event was sponsored by PrimaryBid. The best way to hear about their offers is to register on their website at primarybid.com.

Poolbeg Pharma: Further data shows POLB001 potential in cancer CRS

Poolbeg CEO Jeremy Skillington gave a POLB 001 update & explained how they use AI to speed discovery

Four CEO's present on London South East 8.11.2022: ValiRx, Poolbeg Pharma, enCore Energy, Goldplat

Related Shares

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.